Synonyms: AZD-7624 | Example 259 [WO2009001132]
Compound class:
Synthetic organic
Comment: AZD7624 is a p38α MAPK inhibitor [4]. It was designed as an inhalable agent to provide local anti-inflammatory action in inflammatory lung conditions [2-3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Brough S, Evans R, Luker TJ, Raubo P. (2008)
Pyrazinone derivatives and their use in the treatment of lung diseases. Patent number: WO2009001132A1. Assignee: Astrazeneca. Priority date: 27/06/2007. Publication date: 31/12/2008. |
2. Patel NR, Cunoosamy DM, Fagerås M, Taib Z, Asimus S, Hegelund-Myrbäck T, Lundin S, Pardali K, Kurian N, Ersdal E et al.. (2018)
The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis, 13: 1009-1019. [PMID:29628759] |
3. Pehrson R, Hegelund-Myrbäck T, Cunoosamy D, Asimus S, Jansson P, Patel N, Borde A, Lundin S. (2018)
AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure. J Pharmacol Exp Ther, 365 (3): 567-572. [PMID:29549158] |
4. Raubo P, Evans R, Willis P. (2020)
The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors. Bioorg Med Chem Lett, 30 (18): 127412. [PMID:32717614] |